ArticleFrontiers in neurology2023
Deep brain stimulation for patients with refractory epilepsy: nuclei selection and surgical outcome.
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Mechanism and progress of deep brain stimulation in the treatment of neurological and psychiatric disorders.MedScience · 2026Review
- A guide to neuromodulation in drug-resistant epilepsy.Epileptic disorders : international epilepsy journal with videotape · 2026Review
- Neuromodulation for Epilepsy.Neurologia medico-chirurgica · 2025Review
- Clinical Trials Examining Deep Brain Stimulation for the Treatment of Epilepsy: An Analysis of the Current State.Cureus · 2025Review
- Enhancing seizure control in ultra-refractory postencephalitic epilepsies using multinodal network neuromodulation.Epilepsy & behavior reports · 2025Article
- Inter-seizure variability in thalamic recruitment and its implications for precision thalamic neuromodulation.Communications medicine · 2025Article
- Effect of deep brain stimulation on the severity of seizures and the quality of life in patients with multifocal drug-resistant epilepsy in Iran: A pilot review of local experience.Epilepsy & behavior reports · 2025Article
- Deep brain stimulation of the anterior nucleus of the thalamus for seizures after new-onset refractory status epilepticus: a case report.Frontiers in human neuroscience · 2025Article
- The role of the thalamus in focal human epilepsy: insights from stereoelectroencephalography (SEEG).Frontiers in neurology · 2025Review
- Arachnoid cysts and epilepsy: seizures and epileptogenesis.Neurosurgical review · 2024Review
- Neurostimulation treatments for epilepsy: Deep brain stimulation, responsive neurostimulation and vagus nerve stimulation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- Medial pulvinar stimulation for focal drug-resistant epilepsy: interim 12-month results of the PULSE study.Frontiers in neurology · 2024Article
- Exploring the Role of the Pulvinar Nucleus of the Thalamus in Occipital Lobe Epilepsy: A Case Report.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: By studying the surgical outcome of deep brain stimulation (DBS) of different target nuclei for patients with refractory epilepsy, we aimed to explore a clinically feasible target nucleus selection strategy. Methods: We selected patients with refractory epilepsy who were not eligible for resective surgery. For each patient, we performed DBS on a thalamic nucleus [anterior nucleus of the thalamus (ANT), subthalamic nucleus (STN), centromedian nucleus (CMN), or pulvinar nucleus (PN)] selected based on the location of the patient's epileptogenic zone (EZ) and the possible epileptic network involved. We monitored the clinical outcomes for at least 12 months and analyzed the clinical characteristics and seizure frequency changes to assess the postoperative efficacy of DBS on the different target nuclei. Results: Out of the 65 included patients, 46 (70.8%) responded to DBS. Among the 65 patients, 45 underwent ANT-DBS, 29 (64.4%) responded to the treatment, and four (8.9%) of them reported being seizure-free for at least 1 year. Among the patients with temporal lobe epilepsy (TLE, Significance: ANT-DBS is effective for patients with TLE or ETLE. In addition, ANT-DBS is effective for patients with FBTCS. STN-DBS might be an optimal treatment for patients with motor seizures, especially when the EZ overlaps the sensorimotor cortex. CMN and PN may be considered modulating targets for patients with LGS-like epilepsy or occipital lobe epilepsy, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.